<code id='00BAD4F8E6'></code><style id='00BAD4F8E6'></style>
    • <acronym id='00BAD4F8E6'></acronym>
      <center id='00BAD4F8E6'><center id='00BAD4F8E6'><tfoot id='00BAD4F8E6'></tfoot></center><abbr id='00BAD4F8E6'><dir id='00BAD4F8E6'><tfoot id='00BAD4F8E6'></tfoot><noframes id='00BAD4F8E6'>

    • <optgroup id='00BAD4F8E6'><strike id='00BAD4F8E6'><sup id='00BAD4F8E6'></sup></strike><code id='00BAD4F8E6'></code></optgroup>
        1. <b id='00BAD4F8E6'><label id='00BAD4F8E6'><select id='00BAD4F8E6'><dt id='00BAD4F8E6'><span id='00BAD4F8E6'></span></dt></select></label></b><u id='00BAD4F8E6'></u>
          <i id='00BAD4F8E6'><strike id='00BAD4F8E6'><tt id='00BAD4F8E6'><pre id='00BAD4F8E6'></pre></tt></strike></i>

          
          WSS
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion